A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.

Abstract

OBJECTIVE:

This study evaluated the efficacy and safety of desvenlafaxine succinate extended-release in major depressive disorder (MDD).

METHOD:

Adult outpatients with DSM-IV-defined MDD were randomly assigned to desvenlafaxine 100 mg/day (N = 114), 200 mg/day (N = 116), or 400 mg/day (N = 113) or placebo (N = 118) for 8 weeks. Efficacy variables included change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D(17), the primary efficacy measure), Clinical Global Impressions-Improvement scale (CGI-I), Montgomery-Asberg Depression Rating Scale, Clinical Global Impressions-Severity of Illness scale (CGI-S), rates of response (> or = 50% decrease from baseline HAM-D(17) score) and remission (HAM-D(17) score < or =7), and Visual Analog Scale-Pain Intensity overall score. The study was conducted from November 2003 to November 2004.

RESULTS:

At the final on-therapy evaluation, the mean HAM-D(17) scores for desvenlafaxine 100 mg/day (12.75) and 400 mg/day (12.50) were significantly lower than for placebo (15.31; p = .0038 and p = .0023, respectively); for desvenlafaxine 200 mg/day, the mean score was 13.31 (p = .0764). CGI-I and Montgomery-Asberg Depression Rating Scale results were significant for all groups; CGI-S results were significant with 100 mg/day and 400 mg/day. Response rates were significantly greater for desven-lafaxine 100 mg/day (51%) and 400 mg/day (48%) versus placebo (35%; p = .017 and p = .046, respectively); the response rate for desvenlafaxine 200 mg/day was 45% (p = .142). Remission rates were significantly greater for desvenlafaxine 400 mg/day (32%) versus placebo (19%; p = .035); remission rates were 30% for desvenlafaxine 100 mg/day (p = .093) and 28% for desvenlafaxine 200 mg/day (p = .126). Visual Analog Scale-Pain Intensity results were significant for desvenlafaxine 100 mg/day versus placebo (p = .002), but not for the higher doses. The most commonly reported adverse events were nausea, insomnia, somnolence, dry mouth, dizziness, sweating, nervousness, anorexia, constipation, asthenia, and abnormal ejaculation/orgasm.

CONCLUSIONS:

Desvenlafaxine is effective and well tolerated in the short-term treatment of MDD.

• Authors: Nicholas A DeMartinis, Paul P Yeung, Richard Entsuah, Amy L Manley
• Journal: The Journal of clinical psychiatry (J Clin Psychiatry) Vol. 68 Issue 5 Pg. 677-88 (May 2007) ISSN: 1555-2101 [Electronic] United States
• PMID: 17503976 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antidepressive Agents
• Cyclohexanols
• Desvenlafaxine Succinate

Topics

• Adult
• Antidepressive Agents (adverse effects, therapeutic use)
• Cyclohexanols (adverse effects, therapeutic use)
• Depressive Disorder, Major (drug therapy, psychology)
• Desvenlafaxine Succinate
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Psychiatric Status Rating Scales
• Remission Induction
• Treatment Outcome